Trial Profile

A study of CAP-2003 for the treatment of ocular graft-versus-host disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAP 2003 (Primary)
Indications Graft-versus-host disease
Focus Adverse reactions

Most Recent Events

10 Aug 2017 According to a Capricor Therapeutics media release, company plans to initiate this study in 2018.
13 Sep 2016 New trial record
15 Aug 2016 According to a Capricor Therapeutics media release, the company is planning to file an Investigational New Drug application for CAP-2003 for the treatment of ocular graft-versus-host disease in the first half of 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com